Late Discovery & Investigative Research

NGT BioPharma Consultants understands the challenges companies face when selecting a clinical candidate to advance into preclinical development. To increase the efficiency and effectiveness of this process, we work collaboratively with our clients to provide a clear assessment of an asset’s attributes, including risks, to ensure critical experiments are prioritized. We can then provide a comprehensive plan to navigate the many interdependent preclinical activities, expediting your asset’s path into the clinic.

We leverage our collective expertise and extensive experience in small and large molecules (Mabs, duobodies, proteins, cell therapy, gene therapy as well as new modalities), to generate fit-for-purpose progression plans and provide this consultancy in close alignment with the expertise of NGT consultants experienced in Nonclinical Sciences, CMC, Regulatory and Quality/Compliance disciplines.

Although NGT is neither a laboratory or manufacturing services provider, we can serve as your single point of contact to our network of reputable CROs and CDMOs.

Screen Shot 2022-06-20 at 7.14.10 PM

For more information please contact:

Michael Neeb


Rachel Franckowiak

Senior Director, Administration